Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Orally active direct thrombin inhibitors.

Jeffrey Weitz1

  • 1Henderson Research Centre and McMaster University, Hamilton, Ontario, Canada.

Seminars in Vascular Medicine
|June 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.

Thrombosis and haemostasis·2025
Same author

Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.

Thrombosis and haemostasis·2024
Same author

Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI<sub>Rx</sub> in Patients With ESRD.

Kidney international reports·2022
Same author

Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.

Journal of thrombosis and haemostasis : JTH·2019
Same author

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.

European stroke journal·2019
Same author

Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2018

New oral anticoagulants like ximelagatran offer a predictable response, potentially eliminating the need for monitoring. This contrasts with current vitamin K antagonists, which have limitations in onset and interactions.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Thrombosis Research

Background:

  • Current anticoagulation relies on agents with delayed onset and narrow therapeutic windows, requiring frequent monitoring.
  • Vitamin K antagonists (VKAs) present challenges due to food/drug interactions and the need for precise anticoagulation monitoring.
  • Limitations of VKAs underscore the demand for oral anticoagulants with predictable responses and reduced monitoring needs.

Purpose of the Study:

  • To review the limitations of existing vitamin K antagonists.
  • To define the characteristics of an ideal anticoagulant.
  • To evaluate ximelagatran as a potential new oral anticoagulant targeting thrombin.

Main Methods:

  • Review of preclinical and clinical data for ximelagatran.

Related Experiment Videos

  • Analysis of thrombin as a therapeutic target for anticoagulation.
  • Comparison of ximelagatran's profile with vitamin K antagonists.

    • Main Results:

    • Ximelagatran, a prodrug of melagatran, targets thrombin and shows promise as an ideal anticoagulant.
    • Preclinical and clinical data suggest ximelagatran offers a more predictable anticoagulant response than VKAs.
    • The development of ximelagatran addresses the limitations associated with current oral anticoagulants.

    Conclusions:

    • Ximelagatran presents a potential solution to the challenges posed by vitamin K antagonists.
    • The development of novel oral anticoagulants like ximelagatran is crucial for improved thrombosis management.
    • Further clinical evaluation and perspective on ximelagatran and similar agents are warranted.